A Non-Investigational Product, Multi-Center Cohort Study to Describe Long-Term Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec

Brief summary (registry, in English)

To characterize the long-term safety of participants who have received prior treatment with giroctocogene fitelparvovec or fidanacogene elaparvovec To describe durability of transgene expression of giroctocogene fitelparvovec or fidanacogene elaparvovec

What you commit to

• Study type: Interventional · Phase 3
• Planned participants: 32
• 9 sites in 6 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with hemophilia A or B who already got giroctocogene fitelparvovec or fidanacogene elaparvovec in an earlier Pfizer study. It follows their long-term safety and results.

Age

18 to 64 years

Sex

Men only

Disease stage

Hemophilia A or hemophilia B. The hemophilia B listing says severe to moderately severe (FIX:C ≤ 2%).

Earlier treatment

Must have received giroctocogene fitelparvovec or fidanacogene elaparvovec in a Pfizer-sponsored study.

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 64 years · Sex: Male · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (9)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details